Research Article

Decayed, Missing, and Filled Teeth Index and Periodontal Health in Osteoporotic Patients Affected by BRONJ: An Observational Study

Giacomo Oteri,1 Ennio Bramanti,1 Valentina Nigrone,1 and Marco Cicciù2

1 Department of Biomedical Sciences and Specialist Medical-Surgical Dentistry, University of Messina, Via Consolare Valeria, 98100 Messina, Italy
2 Human Pathology Department, Dental School, University of Messina, Via Consolare Valeria, 98100 Messina, Italy

Correspondence should be addressed to Marco Cicciù; acromarco@yahoo.it

Received 22 September 2013; Revised 6 November 2013; Accepted 7 November 2013

Academic Editor: Manuel Diaz Curiel

Copyright © 2013 Giacomo Oteri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of this paper is to describe the incidence of decayed, missing, and filled teeth (DMFT) and periodontal disease in 32 osteoporotic patients affected by bisphosphonate-related osteonecrosis of the jaw (BRONJ). Moreover, an investigation between the obtained data and 20 patients treated with bisphosphonate drugs and with no evidence of ONJ has been performed. Osteonecrosis of the jaws is a rare complication in a subset of patients receiving bisphosphonate drugs. Based on a growing number of case reports and institutional reviews, this kind of therapy can cause exposed and necrotic bone specifically in the jawbones. From April 2009 to June 2012, 32 osteoporotic patients treated with oral or intravenous (I.V.) bisphosphonates have been recorded. The patients’ oral health has been compared with 20 bisphosphonates patients with no ONJ. The incidence of decayed, missing, and filled teeth (DMFT) and periodontal disease was recorded in all patients and student’s t-test was applied for comparing the two investigated groups data. Data demonstrated how the poor dental hygiene and periodontal disease of the BRONJ patients’ are connected with the occurrence of jawbone necrosis.

1. Introduction

Osteoporosis is a systemic skeletal disorder characterized by skeletal fragility, microarchitectural variation, and low bone mineral density estimated with a T-score for bone mineral density below −2.5 (National Institutes of Health Consensus Conference) [1]. Osteoporosis is one of the most common chronic diseases referred in 1/3 postmenopausal women and 1/5, men over the age of 50 years (European Parliament Osteoporosis Interest Group and EU Osteoporosis Consultation Panel 2004) [2]. Although it is widely recognized that low bone mass is not the only determinant of bone fragility, the strength of the skeleton is influenced by other bone tissue properties, collectively named “bone quality” [3, 4]. Change of bone remodelling pattern in osteoporosis patients resulted in perforation of trabecular plates and loss of cancellous trabecular elements with consequent bone mineral density reduction.

Bisphosphonates are a new class of drugs indicated for use in patients with osteoporosis, Paget’s disease of bone, hypercalcemia in a malignant disease, osteolytic bone metastases, and osteolytic lesions of multiple myeloma. Despite the benefits of bisphosphonate therapy like increasing bone density and preventing bone pathological fractures, osteonecrosis of the jaw is a rare complication in a subset of patients receiving these drugs. This complication often occurs after simple den-toalveolar surgery. The pathogenesis for this complication is still debated. It seems to be related to the profound inhibition of osteoclast function and bone remodelling even if it has been documented also in patients not receiving bisphosphonates [2, 4, 5].

The rationale for the use of bisphosphonates in the postmenopausal patient for osteoporosis management is provided by a sequence of modified biological events [2–5]. The introduction of bisphosphonates therapy for the treatment of bone remodelling diseases has been correlated with the increasing
of bisphosphonate-related osteonecrosis (BRONJ). During the past two decades, BP therapy has become an elective clinical intervention for osteoporosis. Oral BP therapy was prescribed in 73% of 6.3 million visits for osteoporosis in 2003 and it is estimated that over 190 million prescriptions for oral BP have been dispensed in the world [6, 7]. The enzyme target for BPs is farnesyl pyrophosphate synthase by this enzyme inhibition in the osteoclast; BP interferes with geranylgeranylation (attachment of the lipid to regulatory proteins), thus inducing osteoclast inactivation and also apoptosis [8]. Osteoclast inhibition leads to a reduction in bone turnover and the prevention of bone resorption [9]. The potency of osteoclast inhibition is related to the chemical structure of the BP, with nitrogen-containing BPs (including alendronate, risedronate, ibandronate, and zoledronate) being up to 10,000 times more potent than non-nitrogen-containing BPs [10].

This study tested the hypothesis that osteoporotic patients affected by BRONJ have a poorer dental and periodontal history than non-BRONJ patients, analysing them retrospectively, comparing medical and oral history and standardized radiographs.

2. Material and Methods

From April 2007 to June 2012, the oral condition of periodontal health and caries prevalence of 32 osteoporotic patients affected by BRONJ (Figure 1) have been recorded (mean age 60.25 years, range 44–80 years); the same condition was reported for 20 osteoporotic patients (mean age 61.95 years, range 44–80 years) without ONJ. The patients were referred to the "A.O.U Gaetano Martino" dental clinic, the Department of Biomedical Sciences, University of Messina, and Specialist Medical-Surgical Dentistry, from the Geriatric Department of the IRCSS Neurolesi Bonino Pulejo Messina. One of the investigators clinically inspected the oral cavity by performing a periodontal evaluation by using the periodontal screening index (PSI) at four proximal sites per tooth. According to the PSI scores, the findings were diagnosed as follows: scores 0–2 "no periodontitis" and scores 3 and 4 "periodontitis" (Figure 2) [11, 12].

Edentulous patients were not included in the study. Clinical investigation was completed by a mouth mirror for evaluating the presence of dental caries and the number of missed and filled teeth.

Patients were classified as affected by BRONJ according to the American Association of Oral and Maxillofacial Surgeons (AAOMS) guidelines. All the patients included in the study were taking BP for osteoporotic therapy. The questionnaire included age, gender, modality of administration, duration and type of BP, associated pathology, and possible corticosteroid usage. Patients were asked if they had undergone any oral surgical procedure since they started bisphosphonate therapy. The same examiner visited all the patients. The data was collected in a database and the oral check-up recorded dental caries, missing teeth, and filled teeth. The data were classified accordingly with the DMFT index, namely, D (decayed), M (missing), and F (filled) teeth for both groups.

Digital panoramic radiographs were taken of each patient (Orhophos Plus Ds, Sidexis, with image processor Sidexis Next Generation 1.31; Long Island City, NY). The DMFT index was epidemiologically assessed both from the patient's radiograph and through clinical examination [11]. The PSI was taken with the WHO probe which was inserted into the periodontal pocket in the apical direction parallel to the tooth axis [11, 12]. Every tooth was probed at four sites (mesiovestibular, distovestibular, mesiooral, and distooral) and the PSI score (0 to 4) was recorded. The highest score was determined for each sextant. A periodontal pocket deeper than 4 mm was considered a pathologic periodontal condition according to the Community Periodontal Index of Treatment Needs' assessment sequence. The following classifications were made for each participant in this study: PSI scores 0, 1, and 2: "no periodontitis"; PSR/PSI score 3 and 4: "periodontitis."

Student's $t$-test, in statistics, is defined as a method of testing hypotheses about the mean of a small sample drawn from a normally distributed population when the population standard deviation is unknown [13]. For this reason the Student's $t$-test was used to statistically analyse the DMFT index and the PSI score in the groups of the investigated patients.

3. Results and Discussion

A total of 52 patients have been examined. The study involved two groups of patients: A Control Group, 20 osteoporotic patients (16 females, 4 males) without BRONJ (Table 1); B Group, 32 osteoporotic patients (26 females, 6 males) affected by BRONJ (Table 2).

The mean age of BRONJ patients was comparable and similar to the Control Group.
Table 1: Anamnestic and clinical details of A Group—20 osteoporotic non-BRONJ patients.

| Age | OS type | BP therapy | BP (years) | Associated pathology | Corticosteroid assumption | D | M | F | Periodontal probing (mm) |
|-----|---------|------------|------------|----------------------|---------------------------|---|---|---|------------------------|
| 52  | 1       | Ale* + Clo** | 2          | No                   | No                        | 4 | 6 | 6 | 3                      |
| 67  | 1       | Clo** + Ris*** | 3          | Diabetes mellitus II | No                        | 6 | 8 | 5 | 2                      |
| 59  | 2       | Clo**         | 5          | No                   | Yes                       | 3 | 4 | 7 | 5                      |
| 73  | 1       | Ale*          | 6          | No                   | No                        | 3 | 11| 2 | 4                      |
| 77  | 1       | Ale*          | 8          | Rheumatoid arthritis | No                        | 5 | 9 | 5 | 7                      |
| 44  | 1       | Iba****       | 2          | No                   | No                        | 2 | 3 | 4 | 3                      |
| 61  | 1       | Ale*          | 3          | Rheumatoid arthritis | No                        | 4 | 5 | 8 | 4                      |
| 70  | 1       | Clo** + Ris*** + Ner***** | 9           | Hypertension         | No                        | 4 | 10| 6 | 6                      |
| 49  | 1       | Ale* + Clo**  | 4          | No                   | No                        | 3 | 5 | 3 | 2                      |
| 55  | 1       | Ner****       | 3          | No                   | No                        | 4 | 6 | 8 | 7                      |
| 78  | 2       | Ale*          | 6          | Rheumatoid arthritis | Yes                       | 6 | 12| 4 | 9                      |
| 65  | 1       | Ale* + Clo**  | 3          | No                   | No                        | 5 | 7 | 1 | 3                      |
| 52  | 1       | Ris***        | 2          | No                   | No                        | 3 | 4 | 7 | 6                      |
| 80  | 1       | Ale*          | 10         | Cardiovascular diseases | No                      | 2 | 18| 2 | 9                      |
| 66  | 2       | Ale* + Clo**  | 4          | Diabetes mellitus II | Yes                       | 1 | 6 | 9 | 2                      |
| 54  | 1       | Clo** + Ris*** + Ner***** | 4           | No                   | No                        | 3 | 5 | 8 | 4                      |
| 47  | 1       | Ale* + Clo**  | 2          | No                   | No                        | 0 | 2 | 6 | 1                      |
| 71  | 1       | Iba****       | 6          | Diabetes mellitus II | No                        | 2 | 14| 3 | 6                      |
| 59  | 2       | Ale*          | 1          | No                   | Yes                       | 4 | 6 | 5 | 5                      |
| 60  | 1       | Ale* + Clo**  | 3          | Hypertension         | No                        | 3 | 6 | 4 | 6                      |

(i) Ale: alendronate: oral assumption, **Clo: clodronate: oral assumption, ***Ris: risedronate: oral assumption, ****Iba: ibandronate: oral assumption, and *****Ner: neridronate: IV assumption.

(ii) OS type: postmenopausal osteopenia “1”; corticosteroid related osteoporosis “2.”

This was also true for bisphosphonates administration duration that is comparable between the two groups (Control: 4.3 years ± 2.5 years; BRONJ: 4.5 years ± 2.6 years) and the t value did not show any statistical difference in A and B Groups (P = 0.7503) (Figure 3).

D: Number of Decayed Teeth

(i) The number of untreated caries per patient ranged from 0 to 6 in the Control Group with an average of 3.3 ± 1.5 decayed teeth per person (Table 1 and Figure 4).

(ii) The number of untreated caries per patient ranged from 2 to 10 in the BRONJ Group with an average of 5 ± 1.9 decayed teeth per person (Table 2 and Figure 4).

M: Number of Missed Teeth. According to the International Consensus, a complete denture is composed of 28 teeth in the upper and lower jaws, avoiding the presence of the wisdom teeth [14].

(i) The number of missed teeth per patient ranged from 2 to 18 in the Control Group with an average of 7.3 ± 3.9 missed teeth per person (Table 1 and Figure 4).

(ii) The number of missed teeth per patient ranged from 4 to 18 in the BRONJ Group with an average of 10.0 ± 3.8 missed teeth per person (Table 2 and Figure 4).

F: Number of Filled Teeth

(i) The number of filled teeth per patient ranged from 1 to 9 in the Control Group with an average value of 5.1 ± 2.2 teeth (Table 1 and Figure 4).

(ii) The number of filled teeth per patient ranged from 1 to 16 in the BRONJ Group with an average value of 7.9 ± 3.3 teeth (Table 2 and Figure 4).

T: Number of Healthy Teeth

(i) The number of healthy teeth remaining per patient ranged from 10 to 24 in the Control Group with an average value of 16.1 ± 3.8 teeth (Table 1 and Figure 4).

(ii) The number of healthy teeth per patient ranged from 3 to 14 in the BRONJ Group with an average value of 9 ± 3.4 teeth (Table 2 and Figure 4).

Probing Pocket Depth

(i) The periodontal pockets per patient ranged from 1 to 9 mm of depth in the Control Group with an average of 4.7 ± 2.3 mm (Table 1 and Figure 5).

(ii) The periodontal pockets per patient ranged from 4 to 10 mm of depth in the BRONJ Group with an average of 7.0 ± 1.8 mm (deep pocket and severe periodontal disease) (Table 2 and Figure 5).
| Age | OS type | Trigger event | Place of infection | BRONJ stage | BF therapy | BF (years) | Associated pathology | Cortc ST | D | M | F | Period probing (mm) |
|-----|---------|---------------|--------------------|-------------|------------|------------|---------------------|----------|---|---|---|-------------------|
| 66  | 1       | Teeth extract | MAN                | 2           | Ale*       | 6          | Diabetes mellitus II | No       | 4 | 12 | 10 | 7 |                   |
| 60  | 1       | Teeth extract | MAN                | 1           | Ale*       | 5          | Diabetes mellitus II | No       | 6 | 8  | 7  | 6 |                   |
| 56  | 1       | Cyst encl     | MAN                | 1           | Clo**      | 4          | No                  | No       | No| 10 | 5  | 6  | 5 |                   |
| 72  | 1       | Teeth extract | MAS                | 1           | Ale*       | 8          | No                  | No       | No| 4  | 18 | 6  | 7 |                   |
| 80  | 1       | Teeth extract | MAS                | 1           | Ale*       | 11         | No                  | No       | No| 5  | 17 | 1  | 9 |                   |
| 61  | 2       | Teeth extract | MAS                | 3           | Ale* + Clo**| 1         | Rheumatoid arthritis | Yes      | 3 | 11 | 12 | 8 |                   |
| 63  | 1       | Teeth extract | MA                | 2           | Ale*       | 5          | Hypertension         | No       | No| 4  | 14 | 7  | 9 |                   |
| 47  | 1       | Teeth extract | MAS                | 1           | Ale*       | 3          | No                  | No       | No| 10 | 6  | 3  | 10 |                   |
| 51  | 1       | Periodontal infection | MAN | 1           | Ale* + Clo**| 4         | No                  | No       | No| 8  | 4  | 9  | 6 |                   |
| 56  | 1       | Teeth extract | MAN                | 0           | Ale*       | 5          | Rheumatoid arthritis | No       | 3 | 10 | 9  | 9 |                   |
| 49  | 1       | Teeth extract | MAN                | 3           | Ris***     | 2          | No                  | No       | No| 4  | 17 | 4  | 6 |                   |
| 47  | 1       | Implant insertion | MAS | 1           | Ner*****   | 3          | No                  | No       | No| 8  | 4  | 6  | 4 |                   |
| 61  | 1       | Teeth extract | MA                | 1           | Ale*       | 6          | No                  | No       | No| 6  | 11 | 3  | 8 |                   |
| 51  | 1       | Teeth extract | MA                | 1           | Ale*       | 3          | No                  | No       | No| 5  | 8  | 10 | 5 |                   |
| 63  | 1       | Implant removal | MA             | 1           | Ale* + Clo**| 4         | No                  | No       | No| 4  | 9  | 10 | 7 |                   |
| 62  | 1       | Teeth extract | MA                | 2           | Ale* + Clo**| 5         | No                  | No       | No| 5  | 10 | 9  | 9 |                   |
| 69  | 1       | Periodontal infection | MAN | 2           | Ale* + Clo**| 6         | No                  | No       | 5 | 14 | 9  | 5 |                   |
| 75  | 1       | Not identified | MA                | 1           | Ale*       | 9          | Diabetes mellitus II | No       | 6 | 11 | 10 | 9 |                   |
| 77  | 1       | Teeth extract | MA                | 1           | Ale*       | 11         | Rheumatoid arthritis | No       | 5 | 17 | 6  | 8 |                   |
| 74  | 2       | Teeth extract | MA                | 1           | Clo**      | 8          | Hypertension         | No       | 4 | 9  | 5  | 10 |                   |
| 65  | 2       | Teeth extract | MA                | 1           | Clo** + Ris| 4          | Rheumatoid arthritis | Yes      | 3 | 16 | 9  | 5 |                   |
| 67  | 2       | Teeth extract | MA                | 2           | Ale*       | 2          | Rheumatoid arthritis | Yes      | 4 | 6  | 14 | 7 |                   |
| 54  | 2       | Implant insertion | MA             | 1           | Clo** + Ris + Ner***** | 3         | No                  | Yes      | 4 | 8  | 11 | 5 |                   |
| 64  | 1       | Teeth extract | MA                | 0           | Ale*       | 4          | Hypertension         | No       | 7 | 6  | 8  | 9 |                   |
| 59  | 1       | Periodontal infection | MAN | 0           | Ale*       | 2          | No                  | No       | No| 6  | 12 | 4  | 4 |                   |
| 56  | 1       | Teeth extract | MA                | 0           | Iba****    | 4          | No                  | No       | No| 3  | 10 | 7  | 9 |                   |
| 63  | 1       | Teeth extract | MA                | 0           | Iba****    | 3          | No                  | No       | No| 4  | 9  | 6  | 7 |                   |
| 47  | 2       | Teeth extract | MA                | 1           | Ale*       | 2          | No                  | Yes      | 6 | 6  | 9  | 9 |                   |
| 48  | 1       | Teeth extract | MA                | 1           | Ale*       | 1          | No                  | No       | No| 2  | 9  | 8  | 5 |                   |
| 44  | 1       | Implant insertion | MA             | 1           | Ale* + Clo**| 2         | No                  | No       | No| 5  | 8  | 5  | 4 |                   |
| 56  | 1       | Teeth extract | MA                | 1           | Ale* + Clo**| 3         | No                  | No       | No| 4  | 15 | 10 | 9 |                   |
| 65  | 1       | Teeth extract | MA                | 2           | Ale*       | 6          | Rheumatoid arthritis | Yes      | 3 | 9  | 13 | 8 |                   |

(i) Ale: alendronate; oral assumption, ** Clo: clodronate; oral assumption, *** Ris: risedronate; oral assumption, **** Iba: ibandronate; oral assumption, and ***** Ner: neridronate; IV assumption.
(ii) OS type: postMenopausal osteoporosis "1"; Corticosteroid related osteoporosis "2."
Table 3: A Group versus B Group—evaluation of clinical and statistical significance.

| Administration (years) | D       | M       | F       | Periodontal probing (mm) |
|------------------------|---------|---------|---------|--------------------------|
| A Group (osteoporotic patients) | 4.3 (2.49) | 3.35 (1.53) | 7.35 (3.96) | 5.15 (2.28) |
| B Group (BRONJ patients) | 4.53 (2.6) | 5.91 (3.85) | 7.91 (3.34) | 7.06 (1.85) |
| *p value* | 0.75 | 0.001342731 | 0.018622821 | 0.000901775 | 0.000452719 |

Average values ± SD; DMFT index; * statistically significant difference.

Figure 3: Years of BP administration—A and B Groups.

Figure 4: Average number of decayed, missed, and filled teeth recorded for patients in each group.

All of the 32 BRONJ patients of the B Group present a larger and meaningful number of decayed (*p* = .001342731), missed (*p* = .018622821), and filled (*p* = .000901775) teeth (Table 3).

This study shows that the oral health of a consecutive group of BRONJ patients for an oral health check and treatment, generally, has a poorer standard of oral health than bisphosphonate patients with no evidence of ONJ. We tested the hypothesis that the poor periodontal conditions of osteoporotic patients might increase susceptibility to BRONJ.

The American Academy of Oral and Maxillofacial Surgeons defined BRONJ as the presence of necrotic bone in the oral cavity for at least 8 weeks in a patient who is taking (or has taken) BP and who has not received radiation to the head and neck. Four different grades (from 0 to III) of pathology based on clinical severity of symptoms have been identified [15]. Patients affected by BRONJ may have swelling of oral and perioral tissues, pain, bleeding, persistent purulent discharge and draining fistulas, severe halitosis, lower lip paraesthesia, and mobility and loosening of teeth. Patients receiving bisphosphonates who are undergoing dentoalveolar surgery (extractions, dental implant placement, periapical surgery, and periodontal surgery involving osseous injury) are seven times more likely to develop BRONJ than patients who are not having dental surgical procedures [16]. Osteonecrosis of the jaw with oral BP formulations has an estimated incidence of less than one case per 100,000 person-years of exposure. Patients under treatment with oral bisphosphonate therapy have a considerably lower risk of BRONJ than patients treated with IV bisphosphonates. Based on data from the manufacturer of alendronate (Merck), the incidence of BRONJ was calculated to be 0.7/100,000 person/years of exposure. Correspondence with Alastair Goss, DDSc (September 2006), reported that the estimated incidence of BRONJ for patients treated weekly with alendronate is 0.01–0.04%, based on prescription data in Australia. Following extractions, this rate increased to 0.09–0.34%. Other studies pointed out how the incidence of BRONJ in osteoporosis patients taking oral BPs could be significantly higher than previously reported [17]. It has been suggested that BRONJ can be predicted with a combination of environmental and genetic risk factors. Genetic risk factors include polymorphisms of the CYP2C8 gene [18], vascular endothelial growth factor polymorphisms, and mutations in the prothrombin gene [19, 20]. A published case series including at least 10 patients identified in a single city or a limited geographical region showed that 55% of reports come from Mediterranean countries such as Italy (25, 24, and 13 cases; total = 62) [18–21].
While other broader studies on dental and periodontal conditions of patients on bisphosphonates with and without BRONJ including clinical data on the activity and progression of oral diseases might disclose differences that did not reach a statistically significant difference [21], our experimental study found a highly statistically significant difference both of DMFT index and of periodontal probing depth (Table 3).

The incidence of periodontal disease was statistically significant ($P = .000452719$) (Table 3). Furthermore all the BRONJ patients have a pathological periodontal pocket of 4 mm at least (Table 2). The limits of the confidence interval are 6.3 mm and 7.7 mm on average of the probing depth within which there is the a probability of 95% to find the “true” periodontal probing average of BRONJ patients. Prevention by the combination of improving oral health and improved management of their bone disease is the best management of these cases [22–26].

4. Conclusions

This study also shows the fairly simple treatment measures we required for making the patients’ oral cavities healthy. Commonly, this involved extraction of hopeless teeth, endodontics and referral back to their general dentist for simple scaling, and cleaning and oral hygiene instruction.

When extractions were performed the patients had a full informed consent discussion. Extractions should be performed in accordance with the recommendations in the Therapeutic Guidelines, namely, preextraction antibiotic cover, minimal trauma, and suturing of the socket avoiding postoperative complications like bleeding or pain. All the patients were checked after one week and one month. Although some patients had a delayed healing, none developed ONJ [24, 26]. Given that the risk of ONJ for patients on oral bisphosphonates has been calculated in the range of 1 in 225 to 1 in 1100, then the probability of such a study being completed at a single centre is low.

Data results clearly showed how the frequencies of decayed, missed, and filled teeth and periodontal disease were significantly higher in the BRONJ patients group than in the Control Group (Table 3 and Figures 4 and 5).

For this reason, clinicians should recommend patients with osteoporosis paying special attention to the maintenance of their oral hygiene. Regular dental visits are fundamental, with frequent scaling and root planning and conservative, periodontal, and endodontic therapy as needed. Dental extractions should be performed only in the case of hopeless teeth.

The severity of oral health increases with excessive duration of administration of the drug. Black et al. showed that prolonged use of bisphosphonates over five years does not have a therapeutic value because the risk of vertebral fracture remains similar and mineral bone density does not tend to improve [27]. New clinical therapeutic options like growth factor application may be applied for reducing patient pain and for improving the clinical healing after jawbone necrosis [28].

Patients with BRONJ appear to have a higher incidence of periodontal disease and for this reason they should undergo supervised dental care in order to maintain sufficient periodontal attachment without further disease progression. This study highlights how patients with existing untreated periodontal disease and a higher DMFT Index undergoing BP therapy may be at a higher risk for BRONJ and need close supervision and care of their dental condition (Table 3).

Acknowledgment

The authors want to thank Dr. Rahul Tandon DMD for his English grammar correction on the paper text. The clinical study has been approved as an observational study by Bonino Pulejo IRCCS Neurolesi Center with number CE/E/04/2013.

References

[1] NIH Consensus Statement, Osteoporosis Prevention, Diagnosis and Therapy, vol. 17, NIH Consensus Statement, Washington, DC, USA, 2000.
[2] J. Compston, “Action Plan for the prevention of osteoporotic fractures in the European Community,” Osteoporosis International, vol. 15, no. 4, pp. 259–262, 2004.
[3] R. S. Stafford, R. L. Drieling, and A. L. Hersh, “National trends in osteoporosis visits and osteoporosis treatment, 1988–2003,” Archives of Internal Medicine, vol. 164, no. 14, pp. 1525–1530, 2004.
[4] D. Felsenberg and S. Boonen, “The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management,” Clinical Therapeutics, vol. 27, no. 1, pp. 1–11, 2005.
[5] S. L. Ruggiero, B. Mehrotra, T. J. Rosenberg, and S. L. Engroff, “Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases,” Journal of Oral and Maxillofacial Surgery, vol. 62, no. 5, pp. 527–534, 2004.

[6] R. G. Russell, “Bisphosphonates: the first 40 years,” Bone, vol. 49, no. 1, pp. 2–19, 2011.

[7] G. A. Rodan and A. A. Reszka, “Bisphosphonate mechanism of action,” Current Molecular Medicine, vol. 2, no. 6, pp. 571–577, 2002.

[8] R. G. Russell, “Bisphosphonates: mode of action and pharmacology,” Pediatrics, vol. 119, supplement 2, pp. S150–S162, 2007.

[9] S. L. Ruggiero, T. B. Dodson, L. A. Assael, R. Landesberg, R. E. Marx, and B. Mehrotra, “American association of oral and Maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 5, pp. 2–12, 2009.

[10] S. Otto, M. H. Abu-Id, S. Fedele et al., “Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence—a multi-centre study,” Journal of Cranio-Maxillofacial Surgery, vol. 39, no. 4, pp. 272–277, 2011.

[11] T. Becker, L. Levin, T. Shochat, and S. Einy, “How much does the DMFT index underestimate the need for restorative care?” Journal of Dental Education, vol. 71, no. 5, pp. 677–681, 2007.

[12] P. Eickholz, “Clinical periodontal diagnosis: probing pocket depth, vertical attachment level and bleeding on probing,” Perio, vol. 1, no. 1, pp. 75–80, 2004.

[13] J. G. Neely, J. M. Hartman, J. W. Forsen Jr., and M. S. Wallace, “Tutorials in clinical research: VII. Understanding comparative statistics (contrast)-part B: application of t-test, Mann-Whitney U, and chi-square,” Laryngoscope, vol. 113, no. 10, pp. 1719–1725, 2003.

[14] D. L. Brunello and M. N. Mandikos, “Construction faults, age, gender, and relative medical health: factors associated with complaints in complete denture patients,” Journal of Prosthetic Dentistry, vol. 79, no. 5, pp. 545–554, 1998.

[15] M. E. Sarasquete, R. García-Sanz, L. Marín et al., “Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis,” Blood, vol. 112, no. 7, pp. 2709–2712, 2008.

[16] I. Coskun Benlidayi and R. Guzel, “Oral bisphosphonate related osteonecrosis of the jaw: a challenging adverse effect,” ISRN Rheumatology, vol. 2013, Article ID 215034, 6 pages, 2013.

[17] P. Sambrook, I. Olver, and A. N. Goss, “Bisphosphonates and osteonecrosis of the jaw. Position statement on behalf of the Australian and New Zealand Bone Mineral Society, Osteoporosis Australia, Medical Oncology Group of Australia and the Australian Dental Society,” Australian Family Physician, vol. 35, pp. 801–803, 2006.

[18] E. Vairaktaris, S. Vassiliou, D. Avgoustidis, P. Stathopoulos, T. Toyoshima, and C. Yapijakis, “Bisphosphonate-induced avascular osteonecrosis of the Mandible associated with a common thrombophilic mutation in the prothrombin gene,” Journal of Oral and Maxillofacial Surgery, vol. 67, no. 9, pp. 2009–2012, 2009.

[19] M. Manfredi, E. Merigo, R. Guidotti, M. Meleti, and P. Vescovi, “Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis,” International Journal of Oral and Maxillofacial Surgery, vol. 40, no. 3, pp. 277–284, 2011.

[20] G. Favia, G. P. Pilolli, and E. Maiorano, “Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients,” Journal of Rheumatology, vol. 36, no. 12, pp. 2780–2787, 2009.

[21] G. Gasparini, G. Saponaro, F. Di Nardo et al., “Clinical experience with spiramycin in bisphosphonate-associated osteonecrosis of the jaw,” International Journal of Immunopharmacology and Pharmacology, vol. 23, no. 2, pp. 619–626, 2010.

[22] D. Carmagnola, S. Celestino, and S. Abati, “Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology, vol. 106, no. 6, pp. e10–e15, 2008.

[23] S.-B. Woo, J. W. Hellstein, and J. R. Kalmar, “Systematic review: bisphosphonates and osteonecrosis of the jaws,” Annals of Internal Medicine, vol. 144, no. 10, pp. 753–761, 2006.

[24] P. G. Arduino, E. Menegatti, M. Scoletta et al., “Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws,” Journal of Oral Pathology and Medicine, vol. 40, no. 6, pp. 510–515, 2011.

[25] S. E. Pichardo and J. P. van Merkesteyn, “Bisphosphonate related osteonecrosis of the jaws: spontaneous or dental origin?,” Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, vol. 116, no. 3, pp. 287–292, 2013.

[26] A. Dentino, S. Lee, J. Mailhot, and A. F. Hefi, “Principles of periodontology,” Periodontal 2000, vol. 61, no. 1, pp. 16–53, 2013.

[27] D. Black, D. Bauer, A. Schwartz, S. Cummings, and C. Rosen, “Continuing bisphosphonate treatment for osteoporosis—for whom and for how long?” The New England Journal of Medicine, vol. 366, no. 22, pp. 2051–2053, 2012.

[28] M. Cicciù, A. S. Herford, G. Juodžbalys, and E. Stoffella, “Recombinant human bone morphogenetic protein type 2 application for a possible treatment of bisphosphonates-related osteonecrosis of the jaw,” Journal of Craniofacial Surgery, vol. 23, no. 3, pp. 784–788, 2012.